Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 15;66(2):91-102.
doi: 10.36233/0507-4088-33.

[Review of candidate vaccines for the prevention of Lassa fever]

[Article in Russian]
O D Popova  1 , O V Zubkova  1 , T A Ozharovskaia  1 , D I Zrelkin  1 , D V Voronina  1 , I V Dolzhikova  1 , D V Shcheblyakov  1 , B S Naroditsky  1 , D Yu Logunov  1 , A L Gintsburg  1
Affiliations
Review

[Review of candidate vaccines for the prevention of Lassa fever]

[Article in Russian]
O D Popova et al. Vopr Virusol. .

Abstract

The Lassa virus one of the main etiological agent of hemorrhagic fevers in the world: according to WHO estimates, it affects 100,000 to 300,000 people annually, which results in up to 10,000 deaths [1]. Although expansion of Lassa fever caused by this pathogen is mostly limited to the West African countries: Sierra Leone, Liberia, Guinea and Nigeria, imported cases have been historically documented in Europe, the United States of America (USA), Canada, Japan, and Israel [2]. In 2017, WHO included the Lassa virus in the list of priority pathogens in need of accelerated research, development of vaccines, therapeutic agents and diagnostic tools regarding infections they cause [3]. This review describes main technological platforms used for the development of vaccines for the prevention of Lassa fever.

PubMed Disclaimer

LinkOut - more resources